Clinical trials: Brain Tumours
Brain Metastases
Frameless Stereotactic Radiosurgery for Brain Metastases
The investigators plan to study high dose, single treatment radiation, using a plastic mask instead of a head frame that pins into a patient's skull.
- Trial name
- NCT01476878
- Testing
- Frameless Stereotactic Radiosurgery with radiation mask
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Alberta Health services
Quality of Life, Stroke, Acute
Cerebrovascular Disease: Quality of Life (CODE: QoL)
The goal of this observational study is to learn about quality of life, stress and caregiver burden in patients with stroke and their caregivers.
- Conditions
- Quality of Life, Stroke, Acute, Sexual Behavior, Stress
- Trial name
- CODE:QoL (NCT06443268)
- Testing
- questionnaire, hair samples, blood samples, clinical exam
- Where
- Switzerland
- Volunteers
- 680 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Brain Tumors
Study of Massage Therapy Within a Brain Tumor Setting
The purpose of this study is to assess the feasibility and acceptability of massage therapyto examine the effects of massage therapy to explore whether psychological outcomes are associated with changes in patient reported QoL.
- Trial name
- NCT00873184
- Testing
- Massage Therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Duke University
Primary Brain Tumor, Radiation Toxicity
Cognitive Function After Radiation Therapy for Brain Tumours
This study will assess cognitive function in adult patients with a primary brain tumour treated with surgical resection with or without radiation therapy (RT). All types of brain tumours apart from glioblastoma will be included
- Trial name
- WP-12-pre (NCT04118426)
- Testing
- Cognitive testing
- Where
- Denmark
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Brain and Central Nervous System Tumors
Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy, such as temozolomide and irinotecan, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00099125
- Testing
- irinotecan hydrochloride, temozolomide, adjuvant therapy
- Where
- 118 sites in United States
- Volunteers
- 170 people
- Sponsor
- Radiation Therapy Oncology Group
Anti NMDA Receptor Encephalitis
Clinical-immunological Features of Anti-NMDAR Encephalitis
Using a retrospective cohort of 501 patients with anti-NMDAR encephalitis to assess clinical and immunological prognostic biomarkers
- Trial name
- Bio-NMDAr (NCT05738668)
- Testing
- Description of clinical characteristic
- Where
- France
- Volunteers
- 400 people
- Sponsor
- Hospices Civils de Lyon
Furmonertinib, EGFR-mutation
Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE)
This study is a single-arm, open-label, prospective phase II trial. The aim of this phase II study is to evaluate the efficacy and safety of Furmonertinib in patients with EGFR mutation (including 19del or 21L858R or T790M) in…
- Conditions
- Furmonertinib, EGFR-mutation, NSCLC, Brain Metastases
- Trial name
- NCT05465343
- Testing
- Furmonertinib 160 mg, Q.D.
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Peking Union Medical College
Malignant Solid Brain Tumors, Glioblastoma (GBM)
NK Cell Therapy for Malignant Solid Brain Tumors
This is a multi-center, open-label investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, and feasibility of combined intracranial and intravenous administration of ex vivo expanded and activated…
- Conditions
- Malignant Solid Brain Tumors, Glioblastoma (GBM), Glioblastoma Multiforme (GBM), Brain Metastasis
- Trial name
- NCT07552233
- Testing
- Autologous NK cells
- Where
- 4 sites in China
- Volunteers
- 27 people
- Sponsor
- Peking University Third Hospital
Cognitive Impairment, Dementia, Mild
Cognitive Screening Made Easy for PCPs - R33 Phase
This project will facilitate early detection of cognitive decline in older adults through development and implementation of an automated risk assessment and cognitive screening tool for use in primary care.
- Conditions
- Cognitive Impairment, Dementia, Mild, Cognitive Decline
- Trial name
- NCT06162026
- Testing
- RACS app
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- University of Texas at Austin
Brain Tumors, Quality of Life
Bridging the Gap: Using Video Art to Document the Human Face of Disease & Predict Quality of Life Assessments in Brain Tumor Patients
The goal of this study is to explore whether facial expression changes in visual portraits correlate with Quality of Life (QOL) questionnaire responses before and after pet therapy sessions and to compare scores of QOL…
- Conditions
- Brain Tumors, Quality of Life, Animal Assisted Therapy
- Trial name
- NCT02890940
- Testing
- Pet Therapy
- Volunteers
- 13 people
- Sponsor
- Indiana University
Medulloblastoma, Brain Tumors
High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood
The purpose of this study is to evaluate the efficacy of the combination of surgery, conventional chemotherapy, sequential high-dose chemotherapy with peripheral blood stem cell transplantation and reduced dose radiation therapy…
- Conditions
- Medulloblastoma, Brain Tumors, Neuroectodermal Tumors, Primitive
- Trial name
- NCT00180791
- Testing
- Etoposide, carboplatin, melphalan, cisplatin, thiotepa
- Where
- France
- Volunteers
- 71 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Gynecologic Cancer, Chemotherapy Effect
Improve Cancer-related Cognitive Impairment
Cancer-related cognitive impairment (CRCI), also known as "chemobrain," is the cognitive decline that negatively impacts the majority of cancer patients undergoing chemotherapy, radiation, and/or hormonal treatments.
- Conditions
- Gynecologic Cancer, Chemotherapy Effect, Chemo-brain, Cancer-related Cognitive Difficulties
- Trial name
- NCT05864274
- Testing
- Cognitive training application
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Glioblastoma, CNS Disease
Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma
Phase I: Primary Objectives: -To define the maximum tolerated dose (MTD) of dasatinib (Sprycel) with radiotherapy (RT) and 6 weeks of concomitant temozolomide (TMZ) administered at 75 mg/m^2/day in patients with newly-diagnosed…
- Conditions
- Glioblastoma, CNS Disease, Brain Diseases
- Trial name
- NCT00895960
- Testing
- Dasatinib, RT (Radiotherapy), TMZ (Temozolomide)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Brain Tumor Adult, Epilepsy
WISE Cortical Strip for Intraoperative Neurophysiological Monitoring
The WIN Study is a prospective, interventional, multi-center, open-label premarket study designed to confirm the safety, performance and intended use of the WISE Cortical Strip (WCS) for CE certification purposes.
- Trial name
- WIN (NCT03731455)
- Testing
- WISE Cortical Strip
- Where
- 5 sites in Germany, Italy and 1 more
- Volunteers
- 32 people
- Sponsor
- Wise S.r.l.
Brain Metastases, Non-small Cell Lung Cancer
Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung Cancer
Brain metastases, a common complication,occur in 25-40% of patients with non-small cell lung cancer (NSCLC). Whole-brain radiation therapy(WBRT) and Stereotactic Radiosurgery (SRS) are important approaches to the treatment of…
- Trial name
- NCT01688713
- Testing
- Icotinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Neoplasms
Sensitivity of Organoids to Predict Treatment Outcome in Breast Cancer Metastases
The aim of the study is to generate patient-derived organoids (PDOs) from brain resection or biopsied extra-cranial metastases. The preliminary data collected will be used to assess the ability of PDOs to predict patients'…
- Trial name
- PDO (NCT06468124)
- Where
- 2 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- King's College London
Attention Deficit Disorder With Hyperactivity, Asthma
Study of an Intervention to Improve Problem List Accuracy and Use
The aim of this study is to identify patients with problem list gaps and intervene to correct these gaps by creating clinical decision support interventions that alert providers to likely problem list gaps and offer clinicians…
- Conditions
- Attention Deficit Disorder With Hyperactivity, Asthma, COPD, Breast Cancer
- Trial name
- MAPLE (NCT01105923)
- Testing
- MAPLE
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Brigham and Women's Hospital
Critical Illness, Brain Injury
Adverse Events During Physical Therapy in Neurocritical ICU Patients
The goal of this observational study is to identify the clinical, neurological, hemodynamic, and respiratory variables associated with the occurrence of adverse events during physical therapy interventions in adult neurocritical…
- Conditions
- Critical Illness, Brain Injury, Stroke, Subarachnoid Hemorrhage
- Trial name
- NCT07901140
- Testing
- Physical Therapy Intervention
- Where
- 2 sites in Mexico
- Volunteers
- 47 people
- Sponsor
- Hospital H+ Queretaro
Prolactinoma, Prolactin-Producing Pituitary Tumor
PRolaCT - Three Prolactinoma RCTs
This study aims to investigate if endoscopic trans-sphenoidal prolactinoma resection as a first line treatment, or as an equally valid second line treatment after a short (4-6 months) or long (>2 years) period of pretreatment…
- Trial name
- NCT04107480
- Testing
- Endoscopic trans-sphenoidal adenoma resection, Dopamine Agonists
- Where
- 3 sites in Netherlands
- Volunteers
- 880 people
- Sponsor
- Leiden University Medical Center
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
This is a phase I, open label, plus expansion clinical trial evaluating the safety and tolerability of rHSC-DIPGVax in combination with BALSTILIMAB and ZALIFRELIMAB.
- Trial name
- NCT04943848
- Testing
- rHSC-DIPGVax, Balstilimab, Zalifrelimab
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago